TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07155174: A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previou

Sponsor: AbbVie · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT07155174 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07155174 Rescue Dossier →